Skip to content

Investors

A specific analyte, a layered business, a defensible position

Sentos BioMed is a development-stage company building the reference platform for measuring the active form of CRP — with a clear path from product to platform to an inflammation-intelligence business.

The thesis

Why now, why this

A large, underserved question.

CRP testing is among the most-ordered inflammation assays worldwide, yet no widely available test measures the biologically active monomeric form. Sentos aims to own that specific readout. TODO: keep market framing high-level on public page

First-mover specificity.

A binder and method purpose-built for mCRP, with >95% discrimination from pCRP.

Layered value capture.

Product margins fund a platform; the platform generates the data that becomes the long-term asset.

Business model

Product → Platform → Intelligence

Product layer. The mCRP-ALISA™ kit — a consumable with attractive unit economics driven by synthetic-aptamer manufacturing. Investor materials detail gross margins in the data room.

Platform layer. Additional formats (point-of-care, multiplex) extend reach across settings.

Intelligence layer. Longitudinal inflammation data as a durable, compounding asset.

Moats

Five moats

Analyte ownershipPatent-pending IP portfolioClinical evidenceManufacturing know-howData-network effects

(See the Platform page for detail.) We describe IP factually and do not publish portfolio valuations; specifics are available under NDA.

Traction & milestones

Where we are

TODO: public-facing milestone list. Suggested, pending confirmation

  • Core assay characterised; exploratory clinical cohorts completed across four conditions.
  • India patent provisional filed; international strategy defined.
  • Company structure and regulatory roadmap established (Chennai).
  • Next: clinical performance evaluation and CDSCO pathway; EU IVDR planning.

Use of funds (high level)

What capital accelerates

TODO: align with current raise. Suggested high-level buckets

Clinical performance evaluationRegulatory (CDSCO / EU IVDR)Manufacturing scale-up and QMSTeam

No specific amounts or valuations on the public page. Detailed terms and the financial model are shared in the data room.

Request the data room

Qualified investors can request access to detailed materials — including the financial model, IP summary, and regulatory plan — under NDA.

Request the data room →

Or email TODO: investors@sentosbiomed.com